Fullerene (C60)-based X-ray contrast agent for diagnostic imaging
US6660248B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2001 |
| Grant date | Dec 9, 2003 |
| Priority date | — |
| Expiry date | Jan 11, 2022 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/928
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An contrast agent for therapeutic or diagnostic treatment comprises a fullerene scaffold and an iodinated moiety bonded to the scaffold. The agent may further comprise a water solubilizing moiety bonded to the scaffold, which may be a serinol malonodiamide, hydroxyl, and 1,3-diol. The fullerene scaffold may comprise an empty fullerene or an endohedral fullerene. A method for making the agent includes a) synthesizing iodinating moieties, b) protecting serinols, forming protected serinols, c) attaching the protected serinols to the iodinated moieties, forming iodinated serinols, d) attaching the iodinated serinols to the fullerene scaffold, and, optionally, d) de-protecting the serinols. Also disclosed are a method for providing diagnostic treatment to a patient comprising administering to said patient a radiopaque effective amount of a contrast agent comprising a fullerene scaffold and an iodinated moiety, a method of making a blood pool agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.